Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

Coronavirus stocks: Businesses working on COVID-19 cures and treatments

Should your strategy involve the biotechs and health companies that are working toward a cure?


Some of the best-performing — albeit volatile — stocks of the last few weeks are companies that claim to be hunting for a COVID-19 cure.

Biotechs and health companies are among the sectors that will always be needed, even during a recession. Beyond that, investors can’t help but believe that finding a COVID-19 cure would be akin to striking gold — despite the fact that no one knows if a cure will ever be found.

If you’re among the hopefuls, these are the companies leading the way in the search for a COVID-19 cure.

1. Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead is a biopharmaceutical company listed on the NASDAQ that researches, develops and produces new medicines for life-threatening illnesses.

Its stock price jumped in March after the US Food and Drug Administration (FDA) gave it the green light for funding toward one of its experimental drugs (and touted potential cure) Remdesivir. It was set to start enrolling test patients in March 2020, with results out by May.

2. Regeneron (NASDAQ: REGN)

Regeneron Pharmaceuticals is a biotech company focused on developing medicine for a diverse array of diseases.

Its coronavirus response has been twofold: first, developing antibodies to COVID-19 that could help treat or prevent the spread of the coronavirus. Second, a collaboration with Sanofi on an existing treatment that may be able to be utilized for treatment of COVID-19.

The antibody project could begin human testing as early as June, according to reports.

3. Johnson & Johnson (NYSE: JNJ)

Johnson & Johnson is known for providing household healthcare products, but it also works in medical research and development.

In late January, it announced it was working toward the development of a vaccine for COVID-19 through its Janssen Pharmaceutical Companies while collaborating with healthcare regulators.

4. Moderna (NASDAQ:MRNA)

US biotech Moderna is focused on the development of new drugs through stem-cell technology and is one of the first in the world to begin human testing trials for a COVID-19 vaccine.

Its stock price jumped by more than 100% since COVID-19 became a global pandemic as governments in Europe and the US offered large funding rounds in support of its efforts to find a vaccine.

On April 16, the company announced it was receiving a $483 million government grant to accelerate the development and large-scale production of a coronavirus vaccine.

5. Inovio Pharmaceuticals (INO)

Inovio is a US biopharmaceutical company that develops treatments for infectious diseases and cancers.

The company announced in late January it was developing a vaccine for the new coronavirus and was awarded $9 million for its efforts by health regulators. It has since received a further $5 million grant from the Bill & Melinda Gates Foundation and was set to start human trials of a COVID-19 vaccine in April.

6. VIR Biotechnology, Inc. (NASDAQ: VIR)

Immunology company VIR has seen its stock price jump around 60% in March and April, largely on the hopes that it will be the first to find a cure.

In April it announced it was moving forward with two candidates and was due to start human trials between June and August. VIR is also working with Chinese company WuXi Biologics. If a vaccine is approved, it will be commercialized in China through WuXi and marketed to the rest of the world under VIR.

Buy stocks through an online broker

To buy stocks, you’ll need to choose a brokerage account. Compare online stock trading platforms to find one that best suits your needs.

Name Product Available asset types Stock trade fee Option trade fee Annual fee
Stocks,Mutual funds,ETFs,Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
M1 Finance
M1 Finance
A robo-advisor that puts you in the driver’s seat with fully-customizable portfolios.

Compare up to 4 providers

Disclaimer: The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Bottom line

While much of the world is locked down, scientists are busy working on potential treatments and vaccines for COVID-19. There are no guarantees in the high-stakes world of pharmaceuticals, and the COVID-19 outbreak has made stocks especially volatile.

Do your own research before investing in any company and compare your options for trading platforms so you’re not spending unnecessary money on fees.

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site